S&T Bank’s Inovio Pharmaceuticals INO Stock Holding History

S&T Bank’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4	Closed	-$8	–	506
2025 Q2	$8	Hold	4	–	–	﹤0.01%	475
2025 Q1	$7	Buy	+4	New	+$8	﹤0.01%	395

Other funds holding INO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

S&T Bank's INO Position: Q3 2025 in Review

S&T Bank sold out of Inovio Pharmaceuticals (INO) in Q3 2025, closing a stake of 4 shares — an estimated $8 sold.

S&T Bank first reported a position in INO in Q1 2025 and held it in 2 quarters. The position peaked at $8 in Q2 2025. 99 funds tracked by Wall St. Rank hold INO as of Q3 2025.

S&T Bank reported no remaining Inovio Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
S&T Bank sold 4 Inovio Pharmaceuticals shares in Q3 2025, an estimated $8.
S&T Bank first reported a position in Inovio Pharmaceuticals in Q1 2025 and held it in 2 quarters.
S&T Bank's Inovio Pharmaceuticals position peaked at $8 in Q2 2025.
99 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2025.

Based on S&T Bank's 13F filing for Q3 2025, filed 14 Nov 2025.